473A.STU Adaptimmune Therapeutics PLC

- EUR
Market cap
-
P/E
-
P/B
2.63x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2025.

Is 473A.STU undervalued?

Graham number

The Graham number of Adaptimmune Therapeutics PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Adaptimmune Therapeutics PLC fundamental analysis

No fundamental analysis for Adaptimmune Therapeutics PLC yet.

Adaptimmune Therapeutics PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.